Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
Abstract B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Kirja |
| Julkaistu: |
BMC,
2019-04-01T00:00:00Z.
|
| Aiheet: | |
| Linkit: | Connect to this object online. |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
| Hyllypaikka: |
A1234.567 |
|---|---|
| Nide 1 | Saatavissa |